Clinical Trial Update: Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia

View source ↗

Summary

A clinical trial investigating the urokinase plasminogen activator system for benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Snippet

Sponsor: Queen's University | Conditions: BPH | Status: COMPLETED